Skip to content

Anticholinergic Premedication Induced Fever in Pediatric Ambulatory Anesthesia With Ketamine

Anticholinergic Premedication Induced Fever in Pediatric Ambulatory Anesthesia With Ketamine

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02430272
Enrollment
84
Registered
2015-04-30
Start date
2014-05-31
Completion date
2014-12-31
Last updated
2015-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fever

Keywords

Child, outpatient, premedication

Brief summary

Anticholinergic drugs have traditionally been used for their antisialagogue properties. But use of anticholinergic drugs can interfere with thermoregulation via inhibition of the parasympathetically mediated sweat secretion. Sweating inhibition can reduce heat elimination, and children's thermoregulation depend more on sweating than adults and they can become hyperthermic when given these agents. The investigators evaluated the fever-causing effects of adjunctive anticholinergics in children under general anesthesia using ketamine.

Interventions

DRUGGlycopyrrolate

Intravenously administered 0.005mg/Kg of glycopyrrolate in intervention group

Sponsors

Inje University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
12 Months to 8 Years
Healthy volunteers
No

Inclusion criteria

* American Society of Anesthesiologists (ASA) Physical Status classification I * underwent surgery between 8 to 9 am * undergoing ambulatory anesthesia with ketamine

Exclusion criteria

* who required endotracheal intubation * who were administered with medications other than ketamine

Design outcomes

Primary

MeasureTime frameDescription
Body temperatureevery 30 minutes from base line ( up to 90min )measured body temperature at three times in both ears and the highest value was selected.

Secondary

MeasureTime frameDescription
Oral secretion (VAS)up to operative endOral secretion during the whole procedure was recorded by the researcher

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026